COVID‑19’s impact on care practice for alpha‑1‑antitrypsin deficiency patients
Metadatos
Mostrar el registro completo del ítemEditorial
BMC
Materia
COVID-19 Alpha-1-antitrypsin deficiency Recommendations Patient management Healthcare system Rare disease Diagnostic Treatment Follow-up AATD
Fecha
2023-01-30Referencia bibliográfica
Calle Rubio, M... [et al.]. COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients. BMC Health Serv Res 23, 98 (2023). [https://doi.org/10.1186/s12913-023-09094-3]
Patrocinador
CSL BehringResumen
Background Patients with alpha-1 antitrypsin deficiency (AATD), commonly categorized as a rare disease, have been
affected by the changes in healthcare management brought about by COVID-19. This study’s aim was to identify the
changes that have taken place in AATD patient care as a result of the COVID-19 pandemic in Spain and to propose
experts’ recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic
situation.
Methods A qualitative descriptive case study with a holistic single-case design was conducted, using focus groups
with experts in AATD clinical management, including 15 health professionals with ties to the Spanish health system
(12 pneumologists and 2 hospital pharmacists from 11 different hospitals in Spain) and 1 patient representative.
Results COVID-19 has had a major impact on numerous aspects of AATD clinical patient management in Spain,
including diagnostic, treatment, and follow-up phases. The experts concluded that there is a need to strengthen coordination
between Primary Care and Hospital Care and improve the coordination processes across all the organizations
and actors involved in the healthcare system. Regarding telemedicine and telecare, experts have concluded that it
is necessary to promote this methodology and to develop protocols and training programs. Experts have recommended
developing personalized and precision medicine, and patient participation in decision-making, promoting
self-care and patient autonomy to optimize their healthcare and improve their quality of life. The possibility of monitoring
and treating AATD patients from home has also been proposed by experts. Another result of the study was the
recommendation of the need to ensure that plasma donations are made on a regular basis by a sufficient number of
healthy individuals.
Conclusion The study advances knowledge by highlighting the challenges faced by health professionals and
changes in AATD patient management in the context of the COVID-19 pandemic. It also proposes experts’ recommendations
aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. This
work could serve as a reference study for physicians on their daily clinical practice with AATD patients and may also
provide guidance on the changes to be put in place for the post-pandemic situation.





